ROCKVILLE, Md., April 5,
2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a
U.S.-based, global biotech company, exclusively focused on the
development and potential commercialization of highly
differentiated immunotherapies for the treatment of cancer, today
announced that management will present at the 23rd
Annual Needham Virtual Healthcare Conference on April 11, 2024.
23rd Annual Needham Virtual Healthcare
Conference
Presentation
Time
|
Thursday, April
11 at 10:15 a.m. EST
|
Presenters
|
Raj Kannan, CEO; John
Hayslip CMO
|
Webcast link
|
Here
|
Meetings
|
One-on-one and small
group meetings: April 11, 2024
|
Management
Participants
|
Raj Kannan,
CEO
Joe Skelton,
CFO
John Hayslip, CMO
Tyler Ehler, Senior Director, Investor Relations
|
The webcast will also be available under "Event Calendar"
on I-Mab's IR website
at http://ir.i-mabbiopharma.com/
For more information, please contact your Needham
representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company,
exclusively focused on the development and potential
commercialization of highly differentiated immunotherapies for the
treatment of cancer. I-Mab has established operations in
Rockville, Maryland, and in
San Diego, California. For more
information, please visit http://www.i-mabbiopharma.com and follow
us on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-23rd-annual-needham-virtual-healthcare-conference-302108935.html
SOURCE I-Mab Biopharma